SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001737287-24-000050
Filing Date
2024-06-10
Accepted
2024-06-10 16:30:58
Documents
13
Period of Report
2024-06-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20240605.htm   iXBRL 8-K 41853
  Complete submission text file 0001737287-24-000050.txt   167689

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20240605.xsd EX-101.SCH 1989
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20240605_lab.xml EX-101.LAB 21885
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20240605_pre.xml EX-101.PRE 12595
16 EXTRACTED XBRL INSTANCE DOCUMENT allo-20240605_htm.xml XML 2763
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 241033196
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)